多西紫杉醇联合DDP与5-FU治疗晚期胃癌的临床研究  

A clinical study on docetaxel comb med with DDP and 5-FU in the treatment of advanced gastric cancer

作　　者：李丹[1] 曾波航[1] 江素华[1] 

机构地区：[1]广州医学院第二附属医院肿瘤科,广东广州510260

出　　处：《国际医药卫生导报》2008年第8期90-93,共4页International Medicine and Health Guidance News

摘　　要：目的观察多西紫杉醇联合顺铂、5-氟尿嘧啶治疗晚期胃癌的临床疗效和毒性反应。方法28例晚期胃癌患者采用多西紫杉醇75mg／m^2静脉滴注第1天，化疗前预处理，顺铂25mg／m^2静脉滴注第1～3天，5-氟尿嘧啶500mg／m^2静脉滴注第1～5天，每21天为1周期，治疗至少2个周期后评定疗效。结果完全缓解（CR）1例，部分缓解（PR）11例，稳定（SD）10例，进展（PD）6例，总有效率（RR）42．8％，临床受益率71．4％，中位生存期9．1个月。不良反应主要为骨髓抑制，Ⅲ—Ⅳ度粒细胞减少占17．8％，其它毒副反应可以耐受。结论多西紫杉醇联合顺铂和5-氟尿嘧啶治疗晚期胃癌疗效较高，耐受性较好。Objective comined with cisplatin To observe the efficacy and toxicity of docetaxel（DOC） （DDP） and 5 fluorouracil（5-Fu） in the treatment of advanced gastric cancer. Methods 28 patients with advanced gastric cancer were given DOC 75mg/m^2 infusion on day i; DDP 25mg/m^2 on days 1-3; 5-Fu 500 mg/m^2 on days 1-5, and repeated every patients were 21 days, then assessment was done after 2 cycles. Results Of the 28 evaluated, including completed response （CR） was 1 case, partial responses （PR） 11, stable disease （SD） 10, progressing disease （PD） 6, overall response rate （RR） was 42.8%,the clinical benefit percentage was 71.4%,and the median overall survival time was 9.1 months. The main toxicity was bone marrow suppression, the leucopenia of Ⅲ-Ⅳ degrees was 17.8%, other side effects could be tolerated. Conclusion Docetaxel combined with cisplantin and 5-fluorouracil is an effective and well-tolerated regimen for patients with advanced gastric cancer.

关 键 词：多西紫杉醇 顺铂 5-氟尿嘧啶 晚期胃癌 

分 类 号：R735[医药卫生—肿瘤]